Literature DB >> 21481788

Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Marina Lesina1, Magdalena U Kurkowski, Katharina Ludes, Stefan Rose-John, Matthias Treiber, Günter Klöppel, Akihiko Yoshimura, Wolfgang Reindl, Bence Sipos, Shizuo Akira, Roland M Schmid, Hana Algül.   

Abstract

Physiological levels of Kras(G12D) are sufficient to induce pancreatic intraepithelial neoplasias (PanINs); the mechanisms that drive PanIN progression are unknown. Here, we establish that, in addition to oncogenic Kras(G12D), IL-6 transsignaling-dependent activation of Stat3/Socs3 is required to promote PanIN progression and pancreatic ductal adenocarcinoma (PDAC). Myeloid compartment induces Stat3 activation by secreting IL-6; consequently, IL-6 transsignaling activates Stat3 in the pancreas. Using genetic tools, we show that inactivation of IL-6 transsignaling or Stat3 inhibits PanIN progression and reduces the development of PDAC. Aberrant activation of Stat3 through homozygous deletion of Socs3 in the pancreas accelerates PanIN progression and PDAC development. Our data describe the involvement of IL-6 transsignaling/Stat3/Socs3 in PanIN progression and PDAC development.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481788     DOI: 10.1016/j.ccr.2011.03.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  388 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Authors:  Carolyn C Arpin; Stephen Mac; Yanlin Jiang; Huiwen Cheng; Michelle Grimard; Brent D G Page; Malgorzata M Kamocka; Sina Haftchenary; Han Su; Daniel P Ball; David A Rosa; Ping-Shan Lai; Rodolfo F Gómez-Biagi; Ahmed M Ali; Rahul Rana; Helmut Hanenberg; Kagan Kerman; Kyle C McElyea; George E Sandusky; Patrick T Gunning; Melissa L Fishel
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

4.  Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.

Authors:  Kinji Asahina; Steven Balog; Edward Hwang; Eugene Moon; Emily Wan; Kaitlin Skrypek; Yibu Chen; Jay Fernandez; Janet Romo; Qihong Yang; Keane Lai; Samuel W French; Hidekazu Tsukamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-25       Impact factor: 4.052

Review 5.  How Schwann cells facilitate cancer progression in nerves.

Authors:  Sylvie Deborde; Richard J Wong
Journal:  Cell Mol Life Sci       Date:  2017-06-19       Impact factor: 9.261

6.  Transgenic expression of interferon-γ in mouse stomach leads to inflammation, metaplasia, and dysplasia.

Authors:  Li-Jyun Syu; Mohamad El-Zaatari; Kathryn A Eaton; Zhiping Liu; Manas Tetarbe; Theresa M Keeley; Joanna Pero; Jennifer Ferris; Dawn Wilbert; Ashley Kaatz; Xinlei Zheng; Xiotan Qiao; Marina Grachtchouk; Deborah L Gumucio; Juanita L Merchant; Linda C Samuelson; Andrzej A Dlugosz
Journal:  Am J Pathol       Date:  2012-10-01       Impact factor: 4.307

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

8.  mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Authors:  David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

9.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Authors:  Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

Review 10.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.